Multiple sclerosis (MS) is an important example of a specific, limited role for cannabinoid medicines: relieving spasticity for some people. The evidence is not that cannabis cures MS or replaces treatment that changes the course of disease. The clinical research is strongest for particular standardized THC/CBD formulations and a particular symptom.
When signals from brain to muscle are disrupted
To move an arm or a leg, the brain sends signals along nerves. Many nerve fibers are insulated by myelin. In MS, immune-mediated injury to the central nervous system damages myelin and other neural structures, disrupting transmission. Symptoms differ widely and may include altered sensation, weakness, visual problems, fatigue, pain, impaired balance and spasticity.
What is spasticity?
Spasticity is a form of increased muscle tone in which resistance to passive stretching typically increases as the movement becomes faster. A person may experience stiffness, involuntary contractions, spasms and painful or limited movement. At night it can disturb sleep; in severe cases it interferes with walking, sitting, bathing and dressing. The problem lies in altered neural control of the muscles, not necessarily in the muscle itself.
CB1 and the control of movement
The cannabinoid receptor CB1 is present in brain networks involved in movement and neurotransmitter release. Activating these pathways may affect the balance between excitatory and inhibitory signaling. This provides a rationale for examining cannabinoid treatments for the excessive neural activity associated with spasticity.
CB2 and the immune system
MS also involves immune activity within the central nervous system. CB2 participates in immune and inflammatory signaling, which has attracted research interest. But changing an immune mechanism in an experiment is not the same as proving that cannabis halts the disease. The strongest clinical signal so far concerns symptom relief—not disease modification.
What is nabiximols (Sativex)?
Nabiximols, sold as Sativex in some countries, is a standardized cannabis-derived oromucosal spray containing approximately equal amounts of THC and CBD. Much of the MS research concerns products of this kind. Trial results cannot automatically be applied to smoking cannabis flower of a different composition or to other oils with different concentrations.
What do systematic reviews show?
A 2022 Cochrane review of 25 randomized trials involving 3,763 participants concluded that nabiximols probably increases the likelihood of a meaningful improvement in patient-reported spasticity compared with placebo. In an analysis of five trials, the estimated proportion reporting at least a 30% reduction in spasticity was about 50% with cannabinoid treatment versus 29% with placebo over 6–14 weeks. A 2024 meta-analysis drawing on 31 studies also reported improvement in spasticity measures, with nabiximols the most frequently studied product. This suggests a relatively consistent, but not universal, benefit.
Why can patients feel more improvement than an examination detects?
People may report less stiffness, fewer nighttime spasms, improved sleep, less pain or easier movement. A clinician's measurement of muscle resistance cannot necessarily capture all of these experiences. Patient-reported outcomes are therefore an important part of spasticity research. Subjective improvement is meaningful, but should be considered alongside objective measures and adverse effects.
Does cannabis treat MS itself?
No clinical evidence establishes cannabis as a replacement for disease-modifying MS therapies. Those therapies aim to reduce inflammatory disease activity, relapses or new lesions. Cannabinoids used for spasticity serve a different purpose: reducing a symptom. Symptom relief should never be confused with stopping MS progression.
What about neuropathic pain?
MS can cause neuropathic pain, and cannabinoids affect pain pathways. However, the Cochrane review judged evidence for clinically important improvement in chronic neuropathic pain less certain than evidence for spasticity. Evidence for one symptom cannot be carried over automatically to another.
What about fatigue?
There is no simple proof that cannabis restores energy or treats MS fatigue. THC itself can cause drowsiness. Some patients may function better during the day because their nighttime spasms and sleep improve; others may feel more tired because of treatment.
Adverse effects and tolerability
Studies describe dizziness, sleepiness, intoxication, concentration difficulties, nausea, dry mouth and weakness. Cochrane found that cannabinoids may slightly increase stopping treatment due to adverse effects. For people who already have poor balance, a treatment that reduces spasms but increases falls may not improve overall function.
Why do THC:CBD ratios and dose matter?
THC interacts more directly with CB1; CBD may modify aspects of the pharmacological profile but does not necessarily cancel THC effects. Nabiximols supplies a comparatively stable ratio, unlike plant varieties and batches with varying concentrations. Higher doses do not guarantee better function: avoiding excessive dizziness, sedation and unsteadiness is essential.
The bottom line
Certain standardized cannabinoid medications may provide meaningful relief from MS-associated spasticity in some people, with reasonably substantial trial and review evidence. Benefits vary and side effects are real. Cannabis is not established as a cure for MS or a substitute for disease-modifying treatment. The right outcome to assess is practical daily functioning, not simply how much medication a person can take.
Scientific sources
- Cochrane Review: Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Find this source ↗ - Azadvari M, et al. Cannabinoids for spasticity in patients with multiple sclerosis: systematic review and meta-analysis. 2024.
Find this source ↗ - Nabiximols as Add-On Treatment for MS Spasticity: systematic review and meta-analysis.
Find this source ↗
Ask about individual guidance
Speak with our team to find out whether guidance is appropriate for your situation.
WhatsApp ↗